WallStSmart

Novavax Inc (NVAX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novavax Inc generates 80269% more annual revenue ($596.34M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -14.7%. NVAX earns a higher WallStSmart Score of 28/100 (F).

NVAX

Avoid

28

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: -2.65

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVAX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-2.0410/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

NVAX4 concerns · Avg: 2.3/10
Market CapQuality
$1.80B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-898.0%2/10

ROE of -898.0% — below average capital efficiency

Revenue GrowthGrowth
-79.1%2/10

Revenue declined 79.1%

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVAX

The strongest argument for NVAX centers on Debt/Equity. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NVAX

The primary concerns for NVAX are Market Cap, Return on Equity, Revenue Growth.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NVAX profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

NVAX carries more volatility with a beta of 2.37 — expect wider price swings.

NVAX is growing revenue faster at -79.1% — sustainability is the question.

NVAX generates stronger free cash flow (-34M), providing more financial flexibility.

Bottom Line

NVAX scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novavax Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?